AF
XGN icon

Amalgamated Financial’s Exagen XGN Stock Holding History

Amalgamated Financial’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$11K Buy
+1,395
New +$12K ﹤0.01% 2885

Other funds holding XGN

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Amalgamated Financial's XGN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Exagen (XGN) in Q1 2022: 1,395 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #2885 among its holdings.

53 funds tracked by Wall St. Rank hold XGN as of Q1 2022.

  • Amalgamated Financial held 1,395 shares of Exagen worth $11K as of Q1 2022.
  • Exagen was a new Amalgamated Financial position in Q1 2022.
  • Exagen made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2885 holding.
  • 53 funds tracked by Wall St. Rank held Exagen as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.